Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug ...

Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

J&J's Imaavy (nipocalimab-aahu) has received US Food and Drug Administration (FDA) approval for treating generalised ...

The slowdown in IPOs following tariff-associated turbulence and FDA reorganisation will soon pass, say industry investors.

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

When Donald Trump descended a golden escalator at Trump Tower in New York City in 2015 to announce the launch of his first ...

MSD has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in the US state of Delaware.